Evidence map›Paper›PMID 39700476›Full record

ReviewInflammatory bowel diseases2025

Eleven Grand Challenges for Inflammatory Bowel Disease Genetics and Genomics.

Greg Gibson, John D Rioux, Judy H Cho, Talin Haritunians, Akshaya Thoutam, Maria T Abreu, Steven R Brant, Subra Kugathasan, Jacob L McCauley, Mark Silverberg and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Inflammatory bowel diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. IBD risk locus rs1077773 enhances aryl hydrocarbon receptor activity and modulates immune cell function in vitro.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Greg GibsonSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0002-5352-5877
John D RiouxMontreal Heart Institute, Université de Montréal, Montreal, QC, Canada.
Judy H ChoDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Talin HarituniansWidjaja Foundation IBD Research Institute, Cedars Sinai Health Center, Los Angeles, CA, USA.ORCID 0000-0002-9005-7750
Akshaya ThoutamSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
Maria T AbreuHussman Institute for Human Genomics, University of Miami, Miami, FL, USA.
Steven R BrantRobert Wood Johnson School of Medicine, Rutgers University, Piscataway, NJ, USA.
Subra KugathasanDepartment of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-8686-4189
Jacob L McCauleyHussman Institute for Human Genomics, University of Miami, Miami, FL, USA.
Mark SilverbergLunenfeld-Tanenbaum Research Institute IBD, University of Toronto, Toronto, ON, Canada.
Dermot McGovernWidjaja Foundation IBD Research Institute, Cedars Sinai Health Center, Los Angeles, CA, USA.

Funding

IBD Gene Mapping by Clinical and Population SubsetsU01DK062431 · NIDDK · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Steven R Brant · 2002 to 2026
$10.7M
Impact of Genetic Variability on Cellular Pathways and Host-Microbiome InteractioU01DK062423 · NIDDK · SINAI HEALTH SYSTEM · PI MARK S. SILVERBERG · 2002 to 2026
$7.5M
University of Miami IBD Genetic Research Center: Understanding the Genetic Architecture of IBD in the South Florida communityU01DK134201 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Maria Teresa Abreu, Jacob L McCauley · 2022 to 2026
$3.0M
Integrative multi-omic risk assessment at diagnosis and during disease progression in African-Americans with Inflammatory bowel diseaseU01DK134191 · NIDDK · EMORY UNIVERSITY · PI SUBRA KUGATHASAN · 2022 to 2026
$2.8M
NIDDK NIH HHS 5-U01-DK134191NIDDK NIH HHS U01 DK062423NIDDK NIH HHS U01 DK062431NIDDK NIH HHS U01 DK134191NIDDK NIH HHS U01 DK134201
6 · The paper itself

Abstract

The past 2 decades have witnessed extraordinary advances in our understanding of the genetic factors influencing inflammatory bowel disease (IBD), providing a foundation for the approaching era of genomic medicine. On behalf of the NIDDK IBD Genetics Consortium, we herein survey 11 grand challenges for the field as it embarks on the next 2 decades of research utilizing integrative genomic and systems biology approaches. These involve elucidation of the genetic architecture of IBD (how it compares across populations, the role of rare variants, and prospects of polygenic risk scores), in-depth cellular and molecular characterization (fine-mapping causal variants, cellular contributions to pathology, molecular pathways, interactions with environmental exposures, and advanced organoid models), and applications in personalized medicine (unmet medical needs, working toward molecular nosology, and precision therapeutics). We review recent advances in each of the 11 areas and pose challenges for the genetics and genomics communities of IBD researchers.

Indexed as

Genetic Predisposition to DiseaseGenomicsInflammatory Bowel DiseasesPrecision MedicineGenome-Wide Association StudyHumansgenetic epidemiologyIBD GWASintegrative genomicspersonalized genomic medicinepolygenic risk scores

Identifiers

PMID39700476
PMCPMC11700891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.